{"id":34445,"date":"2025-06-23T14:39:24","date_gmt":"2025-06-23T12:39:24","guid":{"rendered":"https:\/\/mabdesign.fr\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/"},"modified":"2025-06-23T14:39:41","modified_gmt":"2025-06-23T12:39:41","slug":"cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/","title":{"rendered":"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region"},"content":{"rendered":"\n

CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. The collaboration could be broadened to include the manufacturing of additional product candidates in Galapagos\u2019 portfolio.
CELLforCURE by SEQENS\u2019 state-of-the-art commercial cell therapy manufacturing facility in Les Ulis, France, will play a key role in supporting Galapagos\u2019 upcoming trials in Paris and the broader France area.<\/p>\n\n\n\n

Galapagos\u2019 Cell Therapy Manufacturing Platform
<\/strong>Galapagos\u2019 innovative decentralized manufacturing platform for cell therapies is designed to be deployed close to cancer treatment centers. By bringing the manufacturing process closer to patients, Galapagos\u2019 platform is designed to deliver fresh, fit, stem-like early memory cell therapy with a median vein-to-vein time of seven days, thereby avoiding cryopreservation and eliminating the need for cytotoxic bridging therapy.<\/p>\n\n\n\n


Strategic Choice of CELLforCURE by SEQENS
<\/strong>The selection of CELLforCURE by SEQENS as a manufacturing partner is based on CELLforCURE\u2019s proven expertise in GMP-compliant commercial-scale cell therapy production. As a recognized player in France, CELLforCURE by SEQENS has worked closely with French hospitals for over five years, actively contributing to the establishment of the first local CAR-T manufacturing pathways in the European Union.
With its strategic location in Les Ulis, near major treatment centers in Paris and the broader France area, CELLforCURE by SEQENS enables Galapagos to realize its ambition of a decentralized manufacturing network bringing treatments closer to patients for faster and more efficient access to care.<\/p>\n\n\n\n


Harnessing Innovation and Experience to Deliver Cell Therapies
<\/strong>\u201cWe are proud and honored to support Galapagos at this pivotal stage of development for GLPG5101\u201d said Marc-Olivier Mignon, President of CELLforCURE by SEQENS. \u201cOur expertise in advanced therapy manufacturing at clinical and commercial stage will support the integration of disruptive cutting-edge technologies as well as the release of a fresh, early-memory-enriched cell therapy.\u201d<\/p>\n\n\n\n

To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.<\/p>\n","protected":false},"author":3,"featured_media":34026,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-34445","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"\nCELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region - MabDesign<\/title>\n<meta name=\"description\" content=\"CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region - MabDesign\" \/>\n<meta property=\"og:description\" content=\"CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T12:39:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-23T12:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2083\" \/>\n\t<meta property=\"og:image:height\" content=\"1175\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region\",\"datePublished\":\"2025-06-23T12:39:24+00:00\",\"dateModified\":\"2025-06-23T12:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\"},\"wordCount\":363,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\",\"name\":\"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg\",\"datePublished\":\"2025-06-23T12:39:24+00:00\",\"dateModified\":\"2025-06-23T12:39:41+00:00\",\"description\":\"CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg\",\"width\":2083,\"height\":1175},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region - MabDesign","description":"CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/","og_locale":"en_US","og_type":"article","og_title":"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region - MabDesign","og_description":"CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.","og_url":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/","og_site_name":"MabDesign","article_published_time":"2025-06-23T12:39:24+00:00","article_modified_time":"2025-06-23T12:39:41+00:00","og_image":[{"width":2083,"height":1175,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg","type":"image\/jpeg"}],"author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region","datePublished":"2025-06-23T12:39:24+00:00","dateModified":"2025-06-23T12:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/"},"wordCount":363,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/","url":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/","name":"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg","datePublished":"2025-06-23T12:39:24+00:00","dateModified":"2025-06-23T12:39:41+00:00","description":"CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications. CELLforCURE by SEQENS, a leading Contract Development and Manufacturing Organization (CDMO) specialized in Advanced Therapy Medicinal Products (ATMPs), is pleased to announce a strategic partnership with Galapagos NV (Euronext & NASDAQ: GLPG) to support the decentralized manufacturing for clinical development of Galapagos\u2019 CD19 CAR T-cell therapy candidate, GLPG5101, investigated in multiple relapsed\/refractory non-Hodgkin lymphoma (NHL) indications.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2025\/06\/CellForCure-by-Seqens_framed_500x282px.jpg","width":2083,"height":1175},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/cellforcure-by-seqens-to-manufacture-galapagos-car-t-cell-therapy-candidates-for-upcoming-trials-expanding-decentralized-network-in-paris-and-the-broader-france-region\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"CELLforCURE by SEQENS to Manufacture Galapagos\u2019 CAR T-Cell Therapy Candidates for Upcoming Trials, Expanding Decentralized Network in Paris and the Broader France Region"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/34445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=34445"}],"version-history":[{"count":1,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/34445\/revisions"}],"predecessor-version":[{"id":34446,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/34445\/revisions\/34446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/34026"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=34445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=34445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=34445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}